2,483 reports of this reaction
5.0% of all PAZOPANIB HYDROCHLORIDE reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for PAZOPANIB HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 2,483 FDA adverse event reports linking PAZOPANIB HYDROCHLORIDE to FATIGUE. This represents approximately 5.0% of all 49,320 adverse event reports for this drug.
Patients taking PAZOPANIB HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among PAZOPANIB HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for PAZOPANIB HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,483 FDA reports for PAZOPANIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 5.0% of all adverse event reports for PAZOPANIB HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking PAZOPANIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.